| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/27/2001 | CN1300738A Polypeptide-rebosome 53 protein 17 and polynucleotide for coding this polypeptide |
| 06/27/2001 | CN1300735A Polypeptide-ribosome 59 protein 26 and polynucleotide for coding this polypeptide |
| 06/27/2001 | CN1300627A Antineoplastic medicine and health-care food containing earthworm plasmin |
| 06/27/2001 | CN1067726C Monoclonal antibody for recognizing interstitial cell surface antigen |
| 06/27/2001 | CN1067722C Adenoviral vectors |
| 06/27/2001 | CN1067687C Polymorphic foams of growth hormone secretagogue |
| 06/27/2001 | CN1067590C Protein granule composition suitable for intravenous injection |
| 06/27/2001 | CN1067589C Protein granules suitable for intravenous injection |
| 06/27/2001 | CN1067588C Clinical application of gamma-interferon in emergency contraception |
| 06/27/2001 | CN1067558C Blood-enriching agent and preparation thereof |
| 06/27/2001 | CN1067550C Calcium receptor active molecules |
| 06/26/2001 | US6253104 Method of preparing pharmaceutical Moxa extract and apparatus for electrical moxibustion using the same extract |
| 06/26/2001 | US6252058 Genetically engineered nucleotide sequences; for the evaluation, diagnosis and treatment of tumors defects |
| 06/26/2001 | US6252056 Membrane protein; for use as diagnostic tools in the treatment of vasospasms |
| 06/26/2001 | US6252055 Generating immunoglobulins; filter immunoglobulin solution through membrane, cycle filtrate through membrane, recover immunoglobulin |
| 06/26/2001 | US6252052 Antibodies which bind to NY-ESO-1 cancer associated proteins, and hybridomas which produce these antibodies |
| 06/26/2001 | US6252051 ErbB4 receptor-specific neuregulin related ligand antibodies and uses therefor |
| 06/26/2001 | US6252048 DNA sequences encoding fusions of DNA repair proteins and uses thereof |
| 06/26/2001 | US6252047 Polypeptide associated with the diagnosis, treatment and prevention of cancer; antitumor agents |
| 06/26/2001 | US6252046 Protein for the treatment of kidney defects |
| 06/26/2001 | US6252044 Riboflavin synthase polypeptide; for the controlled biosynthesis of riboflavin; for screening bactericides; for prevention of infection |
| 06/26/2001 | US6252043 Fusion protein for the treatment of inflammation; for the detection and prevention of leukocyte adhesion to endothelial cells |
| 06/26/2001 | US6252041 Depsipeptides containing non-natural amino acids |
| 06/26/2001 | US6252040 Administering polypeptide |
| 06/26/2001 | US6251957 Preventing neutralizing antibodies; gene therapy |
| 06/26/2001 | US6251939 Carbamate-based cationic lipids |
| 06/26/2001 | US6251902 Dipeptide derivatives as growth hormone secretagogues |
| 06/26/2001 | US6251873 Antisense compounds to CD14 |
| 06/26/2001 | US6251871 Administering pharmaceutical composition comprising adenoviral vector comprising promoter functional in eukaryotic cells and nucleic acid encoding p16 and buffer, solvent or diluent to mammal to inhibit tumor growth |
| 06/26/2001 | US6251869 Enhancement of oxazolidinone antibacterial agents activity by using arginine derivatives |
| 06/26/2001 | US6251868 Method for treating a human immunodeficiency virus infection |
| 06/26/2001 | US6251867 Antiangiogenic peptides and methods for inhibiting angiogenesis |
| 06/26/2001 | US6251866 A water soluble, biocompatible polymer, a chemical agent covalently, releasably coupled to the polymer and an interleukin-2-receptor binding peptide of given sequence covalently coupled to the polymer |
| 06/26/2001 | US6251865 Insulin-like growth factor agonist molecules |
| 06/26/2001 | US6251864 Peptides and compounds that bind to a receptor |
| 06/26/2001 | US6251863 By administering relaxin and glucosamine sulfate to treat osteodegenerative dysfunction in a patient with joint and hip pain; administering relaxin and estrogen to treat alzheimer's |
| 06/26/2001 | US6251861 Treatment of cerebral infarction using cyclic hexapeptides |
| 06/26/2001 | US6251860 Virus-safe human apotransferrin having at least 90% of the theoretical iron binding capacity of iron-free transferrin, contains less than 3% transferrin dimers and no transferrin polymers, and has an iron saturation less than 5% |
| 06/26/2001 | US6251859 Deepithelialized skin diffusion cell system |
| 06/26/2001 | US6251857 Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof |
| 06/26/2001 | US6251854 N-methyl-d-aspartate receptor channel blockers and method for identifying such |
| 06/26/2001 | US6251853 Pertussis toxin (ptx); beta-3 subunit of human g protein with not more than six wd repeat motifs; for the diagnosis of disorders, such as a disease associated with g protein dysregulation (i.e. hypertension) |
| 06/26/2001 | US6251675 Modifying cell by delivering mutant rev gene having mutation from amino acid position 68 to 90 of the wild-type protein; intracellular immunization |
| 06/26/2001 | US6251671 Culturing mammalian spermatogonial stem cells with bone morphogenetic protein 8 to cause proliferation of the stem cells and survival of spermatocytes |
| 06/26/2001 | US6251665 Producing cancer-specific cells by isolating cd34 positive hematopoietic stem cells, incubating in cell culture medium, mixing with tumor cell material, and incubating with tumor necrosis factor-alpha |
| 06/26/2001 | US6251663 Recombinant eukaryotic plasmids containing allergen-gene and use thereof for the prevention and/or treatment of allergic diseases |
| 06/26/2001 | US6251652 Amino acid sequence from staphylococcus cystathionine gamma-lyase gene; drug screening; bactericides; bacteriostats; vaccines; antibodies |
| 06/26/2001 | US6251648 Amino acid sequence of deoxyribonuclease; diagnosis; therapy of respiratory system diseases such as pneumonia and cystic fibrosis |
| 06/26/2001 | US6251645 Leflunomide-resistant helicase; anticarcinogenic agents; antidiabetic agents; immunosuppressants; treatment of alzheimer's disease, atherosclerosis, osteoporosis, autoimmune disorders, and rheumatoid arthritis |
| 06/26/2001 | US6251644 Method for inactivating non-enveloped viral contaminants with a photosensitizer by increasing viral permeability to the photosensitizer |
| 06/26/2001 | US6251633 Polynucleotides encoding Staphylococcus aureus FtsA polypeptide |
| 06/26/2001 | US6251631 Nucleotide sequence coding for ammonia dependent nicotinamide-adenine dinucleotide synthetase; probes for detection of infections |
| 06/26/2001 | US6251630 Polynucleotide encoding member of ribonuclease family of defined amino acid sequence; diagnosis; bacteriostats; bactericides; vaccines; treatment of otitis media, pneumonia, conjunctivitis, bacteremia, meningitis, sinusitis, and others |
| 06/26/2001 | US6251628 Isolated nucleic acid molecules encoding Smad7 |
| 06/26/2001 | US6251627 Antigen presenting system and methods for activation of T-cells |
| 06/26/2001 | US6251603 Evaluating cancer in humans; detect preferential gene expression in tumor, mix sample with antibodies which bind preferential protein, count amount of protein, an amplified protein value indicates adjustment in cancer classification |
| 06/26/2001 | US6251598 Methods for diagnosing sepsis |
| 06/26/2001 | US6251597 Methods for detecting fohy030 |
| 06/26/2001 | US6251585 Assay and reagents for identifying anti-proliferative agents |
| 06/26/2001 | US6251478 Sensitive substance encapsulation |
| 06/26/2001 | US6251438 Method of preparing active substances from nacre, products obtained which can be used in particular as medicaments |
| 06/26/2001 | US6251433 Polycationic polymers |
| 06/26/2001 | US6251419 Membrane system for controlled tissue regeneration in cases of diseases of the periodontium |
| 06/26/2001 | US6251405 Comprising borrelia burgdorferi outer surface protein (osp)c antigen and a second antigenic lipoprotein such as recombinant ospa, or streptococcus pneumoniae cell surface protein (pspa), both in same physio-chemical form |
| 06/26/2001 | US6251402 Administering human chorionic gonadotrophin (hcg) beta-core, deglycosylated hcg, deglycosylated luteinizing hormone, or a mixture thereof |
| 06/26/2001 | US6251399 Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| 06/26/2001 | US6251397 Purified polypeptides encoded by open reading frames (orf's) of a highly virulent strain of the virus as determined by its ability to induce lung lesions in 51.9% of colostrum-deprived piglets; vaccines |
| 06/26/2001 | US6251396 Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
| 06/26/2001 | US6251395 Inhibiting macrophage infiltration at the site of a central nervous system injury such as spinal cord injury by administering an anti-integrin subunit alpha-d monoclonal antibody |
| 06/26/2001 | US6251394 Method and a system for enhanced in vivo clearance of diagnostic and/or therapeutic agents by extracorporeal depletion, and the use of said agents for said purpose |
| 06/26/2001 | US6251393 Conformation-specific anti-von Willebrand Factor antibodies |
| 06/26/2001 | US6251392 Polypeptides for cell targets |
| 06/26/2001 | US6251391 Compositions containing dipepitidyl peptidase IV and tyrosinase or phenylalaninase for reducing opioid-related symptons |
| 06/26/2001 | US6251389 Human nucleotide pyrophosphohydrolase-2 |
| 06/26/2001 | US6251388 Utilization of Wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence |
| 06/26/2001 | US6251387 Topoisomerase I |
| 06/26/2001 | US6251385 Antigen stimulated cells for cancer treatment, free of bodily fluids |
| 06/26/2001 | US6251380 Extraction of plants with methanol, dichloromethane, ethyl acetate, mixing and drying then dilution |
| 06/26/2001 | US6250469 Formulations for protection of peg-interferon alpha conjugates |
| 06/26/2001 | US6250298 Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin |
| 06/26/2001 | CA2245461C Detection of conditions or diseases associated with an altered level of telomerase activity |
| 06/24/2001 | CA2329516A1 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
| 06/23/2001 | CA2329487A1 Assay method |
| 06/21/2001 | WO2001044514A2 Methods and compositions for identifying morphogenic protein analogs using morphogenic protein responsive inhibitory elements |
| 06/21/2001 | WO2001044502A2 Genetic variants of the human fsh receptor and the influence thereof on gametogenesis |
| 06/21/2001 | WO2001044497A2 Protein kinase regulation |
| 06/21/2001 | WO2001044490A2 A NOVEL METHOD TO PRODUCE HUMAN NATURAL INTERFERON-$g(a) |
| 06/21/2001 | WO2001044475A1 Novel polypeptide and dna thereof |
| 06/21/2001 | WO2001044473A2 Polypeptides and nucleic acids encoding same |
| 06/21/2001 | WO2001044472A1 Tnfr/opg-like molecules and uses thereof |
| 06/21/2001 | WO2001044465A2 Therapeutically useful synthetic oligonucleotides |
| 06/21/2001 | WO2001044458A2 Bovine immunodeficiency virus (biv) based vectors |
| 06/21/2001 | WO2001044455A2 Antisense oligonucleotides for the inhibition of expression of type i procollagen |
| 06/21/2001 | WO2001044453A1 25678, a novel human adenylate cyclase |
| 06/21/2001 | WO2001044448A2 Human oxidoreductase proteins |
| 06/21/2001 | WO2001044446A2 Further human alcohol dehydrogenases |
| 06/21/2001 | WO2001044445A2 Human lyases and associated proteins |
| 06/21/2001 | WO2001044443A2 Cytochrome p450rai-2 and related proteins |
| 06/21/2001 | WO2001044297A1 Dna encoding snorf62 and snorf72 receptors |
| 06/21/2001 | WO2001044296A1 Methods of inhibiting the binding of a cd8+ t cell to a class i mhc employing a modified beta 2 microglobulin |